Joe Yeong’s main research focus is to understand and overcome the resistance of immune checkpoint blockade immunotherapy. As an immunopathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and
beyond. He is the pioneer in the automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantify tumor-immune microenvironments in clinical samples. His work on cancer immunology is included in multiple National Medical Research Council-funded studies as well as pharmaceutical industry-sponsored projects. He also served as a committee member on the World Immunotherapy Council and Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium in Washington D.C., USA. He is also a board member of SLAS Technology (Journal), Frontiers, and Pathogens. He serves as a Secretary (Executive) in the Singapore Society of Oncology–Cancer Immunotherapy Consortium, as well as Co-lead of Diagnostic/Education at SingHealth Duke-NUS Cell Therapy Center.
Research Keywords & Expertise
Immunology
Pathology
microenvironment
Immunopathology
Immune-Oncology
Short Biography
Joe Yeong’s main research focus is to understand and overcome the resistance of immune checkpoint blockade immunotherapy. As an immunopathologist, his key vision is to bridge between immunologists and pathologists to better harness the advances of immunotherapy and
beyond. He is the pioneer in the automation of quantitative multiplex immunohistochemistry, using clinical autostainers to study and quantify tumor-immune microenvironments in clinical samples. His work on cancer immunology is included in multiple National Medical Research Council-funded studies as well as pharmaceutical industry-sponsored projects. He also served as a committee member on the World Immunotherapy Council and Society for Immunotherapy of Cancer (SITC) and is one of the organizers for its 2019 WIC Global Symposium in Washington D.C., USA. He is also a board member of SLAS Technology (Journal), Frontiers, and Pathogens. He serves as a Secretary (Executive) in the Singapore Society of Oncology–Cancer Immunotherapy Consortium, as well as Co-lead of Diagnostic/Education at SingHealth Duke-NUS Cell Therapy Center.
Well done!
